New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030
Roots Analysis
FEBRUARY 26, 2024
However, certain biological targets have long eluded drug development efforts. Scientific literature suggests that the RAS gene is mutated across about 30% of cancer types. To learn more, please click New Frontiers Cancer Therapy market report. For further information on this domain, check our report here.
Let's personalize your content